Recalcitrant Issues and New Frontiers in Nano-Pharmacology

Frontiers in Pharmacology

Madhavan Nair¹  Anthony J. McGoron²  Vinay Bhardwaj³  Ajeet Kaushik⁴  Ziad M. Khatib⁵ 

[1] Center for Personalized Nanomedicine, Herbert Wertheim College of Medicine, Florida International University, Miami, FL, United States;Department of Biomedical Engineering, Florida International University, Miami, FL, United States;Department of Biomedical Engineering, The College of New Jersey, Ewing, NJ, United States;Department of Natural Sciences, Florida Polytechnic University, Lakeland, FL, United States;Division of Hematology Oncology, Department of Pediatrics, Nicklaus Children’s Hospital, Miami, FL, United States;

关键词: nanoparticles;    theranostics;    research and development;    nano-based drugs;    Doxil;    nanomedicine;   

DOI  :  10.3389/fphar.2019.01369

来源: DOAJ

【 摘 要 】

Packaging of old pharma drugs into new packaging “nanoparticles” is called nano-pharmacology and the products are called nano-based drugs. The inception of nano-pharmacology research and development (R&D) is marked by the approval of the first nano-based drug Doxil® in 1995 by the Food and Drug Administration. However, even after more than two decades, today, there are only ∼20 nano-based drugs in the market to treat cancers and brain diseases. In this article we share the perspectives of nanotechnology scientists, engineers, and clinicians on the roadblocks in nano-pharmacology R&D. Also, we share our opinion on new frontiers in the field of nano-pharmacology R&D that may allow rapid and efficient transfer of nano-pharma technologies from R&D to market.

【 授权许可】

Unknown